Paroxysmal Nocturnal Hemoglobinuria, High Sensitivity, WBC
Also known as: PNH WBC
Use
This test is used to quantify or monitor the paroxysmal nocturnal hemoglobinuria (PNH) clone size in white blood cells (WBC). It is recommended as the preferred initial diagnostic test for PNH and monitors the effectiveness of treatments, such as Eculizumab, by measuring the PNH clone size in leukocytes, which is crucial for managing patients with PNH, aplastic anemia, and myelodysplastic syndromes.
Special Instructions
Not provided.
Limitations
The assay provides the most accurate measurement of the PNH clone size using WBC. However, the sensitivity may be lower in severely pancytopenic patients. The lower limits of quantification are 0.02 percent for PNH PMNs and 0.5 percent for PNH monocytes. The lower limits of detection are 0.008 percent for PMNs and 0.2 percent for monocytes. The presence of subclinical PNH populations in myelodysplastic bone marrow disorders may correlate with positive immunotherapeutic responses.
Methodology
Cell-based / Cytometry (Flow Cytometry)
Biomarkers
PNH clone size
Other
Result Turnaround Time
1-3 days
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
4 mL
Minimum Volume
4 mL
Container
Lavender (EDTA), pink (K2EDTA), or green (sodium or lithium heparin)
Storage Instructions
Refrigerated
Causes for Rejection
Clotted or hemolyzed specimens.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 24 hours |
| Refrigerated | 72 hours |
| Frozen | Unacceptable |
Other tests from different labs that may be relevant